Get the Stockscreener App
36.81
1.63%
-0.61
Kymera Therapeutics Inc stock is traded at $36.81, with a volume of 394.11K.
It is down -1.63% in the last 24 hours and down -15.77% over the past month.
Kymera Therapeutics Inc is a biotechnology company pioneering a transformative new approach to treating previously untreatable diseases. The company is advancing the field of targeted protein degradation, accessing the body's innate protein recycling machinery to degrade dysregulated, disease-causing proteins. Kymera's Pegasus targeted protein degradation platform harnesses the body's natural protein recycling machinery to degrade disease-causing proteins, with a focus on un-drugged nodes in validated pathways currently inaccessible with conventional therapeutics. It is accelerating drug discovery with an unmatched ability to target and degrade intractable proteins and advance new treatment options for patients.
See More
Previous Close:
$37.42
Open:
$38.37
24h Volume:
394.11K
Relative Volume:
0.84
Market Cap:
$2.38B
Revenue:
$87.56M
Net Income/Loss:
$-167.47M
P/E Ratio:
-15.73
EPS:
-2.34
Net Cash Flow:
$-148.20M
1W Performance:
-0.19%
1M Performance:
-15.77%
6M Performance:
-24.18%
1Y Performance:
-4.81%
1-Day Range:
$36.19
$38.90
1-Week Range:
$36.19
$38.90
52-Week Range:
$29.24
$53.27
Kymera Therapeutics Inc Stock (KYMR) Company Profile
Name
Kymera Therapeutics Inc
Sector
Industry
Phone
857-285-5314
Address
500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN
Compare KYMR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KYMR
Kymera Therapeutics Inc
|
36.81 | 2.38B | 87.56M | -167.47M | -148.20M | -2.34 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Kymera Therapeutics Inc Stock (KYMR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-10-24 | Initiated | BTIG Research | Buy |
| Dec-06-24 | Initiated | BMO Capital Markets | Market Perform |
| Dec-02-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Nov-18-24 | Initiated | Stephens | Overweight |
| Sep-09-24 | Resumed | Leerink Partners | Outperform |
| Aug-26-24 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Apr-22-24 | Initiated | Oppenheimer | Outperform |
| Feb-15-24 | Initiated | Wolfe Research | Peer Perform |
| Jan-04-24 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-03-24 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-19-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jun-30-23 | Initiated | Truist | Buy |
| May-05-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Dec-06-22 | Downgrade | Credit Suisse | Outperform → Neutral |
| Nov-08-22 | Initiated | Raymond James | Mkt Perform |
| Aug-15-22 | Initiated | Jefferies | Buy |
| Aug-03-22 | Initiated | Goldman | Buy |
| Jul-20-22 | Initiated | SVB Leerink | Mkt Perform |
| Apr-28-22 | Initiated | Credit Suisse | Outperform |
| Mar-10-22 | Initiated | JP Morgan | Neutral |
| Feb-10-22 | Initiated | Wells Fargo | Overweight |
| Sep-30-21 | Initiated | B. Riley Securities | Neutral |
| Sep-30-21 | Initiated | Stifel | Buy |
| Sep-10-21 | Downgrade | BofA Securities | Buy → Neutral |
| May-21-21 | Initiated | UBS | Buy |
| Apr-14-21 | Initiated | Berenberg | Buy |
| Dec-04-20 | Initiated | H.C. Wainwright | Buy |
| Sep-15-20 | Initiated | BofA Securities | Neutral |
| Sep-15-20 | Initiated | Cowen | Outperform |
| Sep-15-20 | Initiated | Guggenheim | Buy |
| Sep-15-20 | Initiated | Morgan Stanley | Equal-Weight |
View All
Kymera Therapeutics Inc Stock (KYMR) Latest News
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Kymera Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on February 27 - The Manila Times
Kymera Therapeutics (KYMR) Expected to Announce Earnings on Thursday - MarketBeat
Kymera Therapeutics: Plenty Of Potential, But A Long Way From The Finish Line (KYMR) - Seeking Alpha
When the Price of (KYMR) Talks, People Listen - Stock Traders Daily
Getting In Cheap On Kymera Therapeutics, Inc. (NASDAQ:KYMR) Is Unlikely - Simply Wall St
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
Kymera rises after presentation at the J.P. Morgan event - MSN
SG Americas Securities LLC Trims Stock Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - MarketBeat
Jennison Associates LLC Trims Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - MarketBeat
Head to Head Review: Kymera Therapeutics (NASDAQ:KYMR) & Gene Biotherapeutics (OTCMKTS:CRXM) - Defense World
Financial Snapshot: Analyzing Kymera Therapeutics Inc (KYMR)’s Key Ratio Metrics - The Dwinnex
Long Term Trading Analysis for (KYMR) - Stock Traders Daily
SG Americas Securities LLC Cuts Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Kymera Therapeutics to Participate in Upcoming February Investor Conferences - The Manila Times
Inside Kymera's Upcoming Biotech Presentations: Key Investor Events You Can't Miss - StockTitan
(KYMR) Technical Data - Stock Traders Daily
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives $55.06 Average PT from Brokerages - Defense World
Brokerages Set Kymera Therapeutics, Inc. (NASDAQ:KYMR) Price Target at $55.06 - MarketBeat
Kymera Therapeutics (NASDAQ:KYMR) Earns "Overweight" Rating from Stephens - MarketBeat
Kymera announces expansion of KT-474 HS and AD phase 2 studies - MSN
Kymera Therapeutics soars as Sanofi expands phase 2 trials - MSN
Kymera Therapeutics (NASDAQ:KYMR) Trading Down 6.3%Time to Sell? - MarketBeat
Kymera Therapeutics (NASDAQ:KYMR) Provides Business Update and Preliminary Cash Balance for 2024 - Defense World
Kymera Therapeutics (KYMR) Moves 7.8% Higher: Will This Strength Last? - MSN
Kymera Therapeutics describes IRAK-4 degraders - BioWorld Online
How the (KYMR) price action is used to our Advantage - Stock Traders Daily
JPMorgan Chase & Co. Acquires 95,547 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World
Kymera Provides Pipeline Objectives for 2025, Stock Gains - MSN
Kymera Therapeutics Surges 10% on Bold 2025 Roadmap to Revolutio - GuruFocus.com
Kymera stock surges on product pipeline update By Investing.com - Investing.com Canada
Kymera Therapeutics Surges 10% on Bold 2025 Roadmap to Revolutionize Immunology Treatments - Yahoo Finance
Kymera Therapeutics (NASDAQ:KYMR) Trading 6.4% HigherHere's Why - MarketBeat
Kymera reports progress in immunology drug trials By Investing.com - Investing.com South Africa
Kymera Therapeutics Shares Surge Amid 2025 Strategy Unveil - TipRanks
Kymera reports progress in immunology drug trials - Investing.com India
Kymera Therapeutics Outlines Key 2025 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs - The Manila Times
Kymera Unveils Ambitious 2025 Immunology Pipeline Plans with $850M Cash Runway - StockTitan
Analysts Set Expectations for KYMR FY2029 Earnings - Defense World
Stifel sustains Buy on Kymera stock amid TPD drug optimism By Investing.com - Investing.com UK
Equities Analysts Set Expectations for KYMR FY2029 Earnings - MarketBeat
Kymera Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14 - The Manila Times
Kymera Therapeutics to Present Strategic Roadmap at J.P. Morgan Healthcare Conference - StockTitan
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Insider Sells $130,635.75 in Stock - MarketBeat
(KYMR) Trading Report - Stock Traders Daily
STAT6 stat sig? Kaken, J&J $1.2B-plus deal adds oomph to space - BioWorld Online
Kymera Therapeutics Inc Stock (KYMR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Kymera Therapeutics Inc Stock (KYMR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Jacobs Bruce N. | Chief Financial Officer |
Jan 10 '25 |
Option Exercise |
2.08 |
10,000 |
20,800 |
178,921 |
| Chiniara Ellen | Chief Legal Officer |
Jan 06 '25 |
Sale |
41.75 |
3,129 |
130,645 |
54,826 |
0.27%
3.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):